Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients

This segment explores how real world outcomes with CAR T-cell therapy in multiple myeloma compare with results seen in clinical trials, particularly for older adults and patients with comorbidities. Dr. Kaur notes that real world data have been reassuring, showing that patients treated outside of trial settings often achieve efficacy outcomes that closely mirror those reported in pivotal studies. Importantly, advanced age alone is not a barrier; patients in their late seventies and eighties, and even older, can successfully undergo CAR T when cardiovascular and pulmonary function are adequate and support systems are strong. Comorbid conditions such as compensated heart failure or chronic kidney disease are manageable with appropriate dose adjustments and multidisciplinary coordination. Toxicities like CRS and neurotoxicity remain predictable and generally occur within the monitored window. These consistent real world outcomes highlight that CAR T-cell therapy is both feasible and effective for a broader population than those traditionally enrolled in trials, supporting its use across diverse patient groups.